Stocks
Rallybio CorporationRLYB
NASDAQHealthcareBiotechnology$16.64
Price as of · delayed, not real-time
A clinical-stage biotechnology company developing therapies for rare diseases, with a lead program targeting fetal and neonatal alloimmune thrombocytopenia (FNAIT). Its pipeline also includes treatments for complement-mediated disorders and other severe conditions. Investors track Rallybio for its orphan drug focus and upcoming clinical data readouts.
52W Range: $3.67-$17.57
Congressional Interest in Rallybio Corporation (RLYB)
No congressional trades have been disclosed for Rallybio Corporation (RLYB) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading RLYB?
No congressional trades found for this stock.